Table 1 Baseline characteristics of right-sided colon cancer patients with preoperative low and high ALI.

Age, n (%)

0.015

0.399

 ≤60 years

207 (46.9)

98 (41.5)

109 (53.2)

186 (51.7)

89 (49.4)

97 (53.9)

 >60 years

234 (53.1)

138 (58.5)

96 (46.8)

174 (48.3)

91 (50.6)

83 (46.1)

Gender, n (%)

0.815

0.672

 Male

234 (53.1)

124 (52.5)

110 (53.7)

194 (53.9)

95 (52.8)

99 (55.0)

 Female

207 (46.9)

112 (47.5)

95 (46.3)

166 (46.1)

85 (47.2)

81 (45.0)

ASA classification, n (%)

0.203

0.115

 1+2

410 (93.0)

216 91.5)

194 (94.6)

332 (92.2)

162 (90.0)

170 (94.4)

 3+4

31 (7.0)

20 (8.5)

11 (5.4)

28 (7.8)

18 (10.0)

10 (5.6)

Preoperative anemia

275 (62.4)

165 (69.9)

110 (53.7)

<0.001

223 (61.9)

125 (69.4)

98 (54.4)

0.003

Preoperative CEA, n (%)

0.430

0.748

 ≤5 ng/ml

271 (61.5)

141 (59.7)

130 (63.4)

213 (59.2)

105 (58.3)

108 (60.0)

 >5 ng/ml

170 (38.5)

95 (40.3)

75 (36.6)

147 (40.8)

75 (41.7)

72 (40.0)

Preoperative CA19-9, n (%)

0.119

0.895

 ≤37 U/ml

347 (78.7)

179 (75.8)

168 (82.0)

289 (78.7)

145 (80.6)

144 (80.0)

 >37 U/ml

94 (21.3)

57 (24.2)

37 (18.0)

71 (21.3)

35 (19.4)

36 (20.0)

Diabetes, n (%)

101 (15.3)

7 (14.6)

94 (15.3)

0.889

53 (14.7)

28 (15.6)

25 (13.9)

0.655

Hypertension, n (%)

186 (28.1)

14 (29.2)

172 (28.1)

0.869

102 (28.3)

47 (26.1)

55 (30.6)

0.349

Surgical approach, n (%)

0.001

0.004

 Laparoscopic

317 (71.9)

154 (65.3)

163 (79.5)

255 (29.2)

115 (63.9)

140 (77.8)

 Open

124 (28.1)

82 (34.7)

42 (20.5)

105 (70.8)

65 (36.1)

40 (22.2)

Tumor location, n (%)

0.242

0.598

 Ileocecal /ascending colon

217 (49.2)

110 (46.6)

107 (52.2)

179 (49.7)

87 (48.3)

92 (51.1)

 Hepatic flexure colon

224 (50.8)

126 (53.4)

98 (47.8)

181 (50.3)

93 (51.7)

88 (48.9)

Total retrieved LNs

0.404

0.723 ^a

 <12

12 (2.7)

5 (2.1)

7 (3.4)

8 (2.2%)

3 (1.7%)

5 (2.8%)

 ≥12

429 (97.3)

231 (97.9)

198 (96.6)

352 (97.8%)

177 (98.3%)

175 (97.2%)

Operative time, n (%)

0.527

0.398

 ≤205 min

208 (47.2)

108 (45.8)

100 (48.8)

166 (46.1)

79 (43.9)

87 (48.3)

 >205 min

233 (52.8)

128 (54.9)

105 (51.2)

194 (53.9)

101 (56.1)

93 (51.7)

Estimated blood loss, n (%)

0.221

0.292

 ≤55 ml

225 (51.0)

114 (48.3)

111 (54.1)

182 (50.6)

86 (47.3)

96 (53.3)

 >55 ml

216 (49.0)

122 (51.7)

94 (45.9)

178 (49.4)

94 (52.2)

84 (46.7)

pT stage, n (%)

<0.001

0.684

 T1+2

48 (10.9)

12 (5.1)

36 (17.6)

26 (10.9)

12 (6.7)

14 (7.8)

 T3+4

393 (89.1)

224 (94.9)

169 (82.4)

334 (89.1)

168 (93.3)

166 (92.2)

pN stage, n (%)

0.413

0.590

 N0

248 (56.2)

128 (54.2)

120 (58.5)

205 (56.9)

100 (55.6)

105 (58.3)

 N+

193 (43.8)

108 (45.8)

85 (44.3)

155 (43.1)

80 (44.4)

75 (41.7)

pTNM stage, n (%)

0.004

0.762

 I

39 (9.5)

11 (8.3)

28 (9.6)

25 (9.5)

11 (6.1)

14 (7.8)

 II

209 (46.5)

117 (54.2)

92 (45.7)

180 (46.5)

89 (49.4)

91 (50.6)

 III

193 (44.0)

108 (37.5)

85 (44.7)

155 (44.0)

80 (44.5)

75 (41.7)

Tumor differentiation, n (%)

0.014

0.673

 Grade 1+2

399 (90.5)

206 (87.3)

193 (94.1)

336 (93.3)

167 (92.8)

169 (93.9)

 Grade 3+4

42 (9.5)

30 (12.7)

12 (5.9)

24 (6.7)

13 (7.2)

11 (6.1)

Histopathology, n (%)

0.960

0.521

 Adenocarcinoma

263 (59.6)

141 (59.7)

122 (59.5)

210 (90.5)

108 (60.0)

102 (56.7)

 Mucinous/signet ring cell adenocarcinoma

178 (40.4)

95 (40.3)

83 (40.5)

150 (9.5)

72 (40.0)

78 (43.3)

Nerval invasion, n (%)

46 (16.3)

26 (11.0)

20 (9.8)

0.666

36 (10.0)

17 (9.4)

19 (10.6)

0.725

Lymphovascular invasion, n (%)

67 (19.2)

40 (16.9)

27 (13.2)

0.270

48 (13.3)

24 (13.3)

24 (13.3)

0.270

Adjuvant chemotherapy

295 (66.9)

165 (69.9)

130 (63.4)

0.148

242 (67.2)

123 (68.3)

119 (66.1)

0.653

Postoperative hospital stays, mean (SD)

8.88 (5.35)

9.61 (5.44)

8.23 (5.47)

0.009

8.82 (5.30)

9.53 (4.97)

8.14 (5.528)

0.014